SharesGrow.com Intrinsic Value of S&P & Nasdaq Contact Us

हिन्दी

← Back to all stocks

Cellyan Biotechnology Co., Ltd HKPD NASDAQ

NASDAQ Capital Marke • Healthcare • Medical - Pharmaceuticals • HK • USD

SharesGrow Score

SharesGrow Intrinsic Value

Negative cash flow

Cellyan Biotechnology Co., Ltd (HKPD) is a Medical - Pharmaceuticals company in the Healthcare sector, currently trading at $0.69. It has a SharesGrow Score of 42/100, indicating a mixed investment profile with 0 out of 7 criteria passed.

Valuation: HKPD trades at a trailing Price-to-Earnings (P/E) of -178.7 (S&P 500 average ~25) with a forward Price/Earnings-to-Growth (PEG) of 1.79.

Financials: revenue is $20M, +27.3%/yr average growth. Net income is $27,056 (loss), growing at -34.4%/yr. Net profit margin is -0.1% (negative). Gross margin is 11.9% (-9.9 pp trend).

Balance sheet: total debt is $2M against $5M equity (Debt-to-Equity (D/E) ratio 0.48, conservative). Current ratio is 2.99 (strong liquidity). Debt-to-assets is 25.2%. Total assets: $9M.

SharesGrow 7-Criteria breakdown: Value 53/100 (Partial), Growth 58/100 (Partial), Past 67/100 (Partial), Health 67/100 (Partial), Moat 7/100 (Fail), Future ?/100 (Fail), Income 10/100 (Fail).

HKPD SharesGrow Score Overview

44/100

SharesGrow Score

Mixed signals — some strengths

View full scorecard →

VALUE 53/100

Valuation — P/E, PEG, Forward PEG

GROWTH 58/100

Financials — average growth

PAST 67/100

strong — trend

HEALTH 67/100

Balance sheet — Debt-to-Equity (D/E) ratio, Current ratio is

MOAT 7/100

Gross margin is + market cap

FUTURE 0/100

Analyst outlook — as buy

INCOME 10/100

Net profit margin is

Scores derived from financial statements, analyst ratings, and balance sheet data.

Score Breakdown — HKPD

HKPD trades at a trailing Price-to-Earnings (P/E) of -178.7 (S&P 500 average ~25). Forward PEG 1.79 — overvalued. Trailing PEG 1.79. Composite: Price-to-Earnings (20%) + Forward Price/Earnings-to-Growth (35%) + upside (25%) + trailing PEG (20%). ≥ 60 = Pass.

View details →

HKPD: +27.3%/yr revenue is, -34.4%/yr Net income is average growth. mixed. Score: >20%/yr = 100, >10% = 80, >5% = 65, >0% = 45, < 0 = 15.

View details →

HKPD: 2 / 3 years profitable. mixed. Score = 2 / 3 × 100. ≥ 80 = Pass.

View details →

Balance sheet HKPD: Debt-to-Equity (D/E) ratio 0.48 (conservative), Current ratio is 2.99 (strong liquidity). Debt-to-Equity < 0.5, Current Ratio > 1.5, Interest Coverage > 8x = ideal. ≥ 70 = Pass.

View details →

HKPD: Gross margin is 11.9% (-9.9 pp trend), N/A market cap. Moat (0-100): margin (35%) + trend (15%) + market cap (30%) + revenue is (20%). Score 7/100. ≥ 70 = Pass.

View details →

No analyst coverage available for this stock.

HKPD: Net profit margin is -0.1%. negative. Score: ≥30% = 100, ≥20% = 85, ≥15% = 70, ≥10% = 55, ≥5% = 45, ≥0% = 30, < 0 = 10.

View details →

Stock Chart & Stats

Market Data

52-Week Range0.37-2.76

Volume46.48K

Avg Volume (30D)40.15K

Market Cap$7.63M

Beta (1Y)3.80

Share Statistics

EPS (TTM)0.00

Shares Outstanding$9.02M

IPO Date2025-01-15

Employees27

CEOChenyu Liang

Financial Highlights & Ratios

Revenue (TTM)$20.31M

Gross Profit$2.42M

EBITDA$1.21M

Net Income$-27.06K

Operating Income$132.04K

Total Cash$3.01M

Total Debt$2.37M

Net Debt$1.63M

Total Assets$9.42M

Price / Earnings (P/E)-257.4

Price / Sales (P/S)0.38

Analyst Forecast

Company Info

CountryHK

ExchangeNASDAQ Capital Marke

CurrencyUSD

ISINKYG6365B1041

Price Chart

HKPD

Cellyan Biotechnology Co., Ltd ↗ · NASDAQ Capital Marke

Healthcare • Medical - Pharmaceuticals

0.37 52WK RANGE 2.76

People Also View

Freightos Limited Ordinary shares

New Century Logistics (BVI) Limited

PS International Group Ltd.

Art's-Way Manufacturing Co., Inc.

Universal Safety Products, Inc.

Lakeside Holding Limited

Jayud Global Logistics Limited

Contact Us

🎓

SharesGrow Academy

Learn how to calculate Intrinsic Value and find undervalued stocks.

Weekly live sessions

📧 [email protected]

📞 +65 8912 8000

Send us a message